Top

Clinical Pharmacokinetics

Published in:

01-07-2006 | Original Research Article

Morphine Metabolite Pharmacokinetics during Venoarterial Extra Corporeal Membrane Oxygenation in Neonates

Authors: Dr Jemen W. B. Peters, Brian J. Anderson, Sinno H. P. Simons, Donald R. A. Uges, Dick Tibboel

Published in: Clinical Pharmacokinetics | Issue 7/2006

Abstract

Objective

To examine morphine metabolite serum concentrations in neonates undergoing venoarterial extra corporeal membrane oxygenation (ECMO) and to quantify clearance differences between these neonates and those subjected to noncardiac major surgery.

Patients and methods

This was an observational study in level III referral centre. Fourteen neonates (<7 days old) undergoing ECMO were included. Morphine and concomitant medications were given by protocol, adapted to the clinical conditions of the neonates. Pharmacokinetic findings were compared with those from a previous study in infants after noncardiac major surgery. Nonlinear mixed-effect modelling was used. Parameter estimates were standardised to a 70kg person using allometric modeling

Results

Morphine-3-glucuronide (M3G) was the predominant metabolite. Formation clearance to M3G at the start of ECMO on day 1 was lower than those in postoperative children, but matured more rapidly. After 10 days formation clearances of M3G in neonates on ECMO equalled those of postoperative children. Higher ECMO flows were associated with reduced formation clearances. Elimination clearances of M3G, but not morphine-6-glucuronide (M6G), were lower in the ECMO neonates; this was attributable to reduced renal clearance. These elimination clearances were correlated positively with ECMO flow and negatively with dopamine dose. Haemofiltration cleared M3G and M6G, but not morphine.

Conclusion

Formation clearance to M3G, the predominant metabolite, is reduced during the first 10 days of ECMO. Elimination clearance of M3G and M6G is related to creatinine clearance. ECMO flow had a small effect on metabolite clearance. Higher flows were associated with decreased formation clearances, possibly reflecting illness severity. Dopamine dose reflected decreased renal clearance.

Available only for authorised users

Iyer LV, Ho MN, Shinn WM, et al. Glucuronidation of 1′-hydroxyestragole (1′-HE) by human UDP-glucuronosyltrans-ferases UGT2B7 and UGT1A9. Toxicol Sci 2003; 73: 36–43PubMedCrossRef

Green MD, King CD, Mojarrabi B, et al. Glucuronidation of amines and other xenobiotics catalyzed by expressed human UDP-glucuronosyltransferase 1A3. Drug Metab Dispos 1998; 26: 507–12PubMed

Frances B, Gout R, Monsarrat B, et al. Further evidence that morphine-6 beta-glucuronide is a more potent opioid agonist than morphine. J Pharmacol Exp Ther 1992; 262: 25–31PubMed

Paul D, Standifer KM, Inturrisi CE, et al. Pharmacological characterization of morphine-6 beta-glucuronide, a very potent morphine metabolite. J Pharmacol Exp Ther 1989; 251: 477–83PubMed

Smith MT, Watt JA, Cramond T. Morphine-3-glucuronide: a potent antagonist of morphine analgesia. Life Sci 1990; 47: 579–85PubMedCrossRef

Labella FS, Pinsky C, Havlicek V. Morphine derivatives with diminished opiate receptor potency show enhanced central excitatory activity. Brain Res 1979; 174: 263–71PubMedCrossRef

Snead III OC. Opiate-induced seizures: a study of mu and delta specific mechanisms. Exp Neurol 1986; 93: 348–58PubMedCrossRef

Woolf CJ. Intrathecal high dose morphine produces hyperalgesia in the rat. Brain Res 1981; 209: 491–5PubMedCrossRef

Yaksh TL, Harty GJ, Onofrio BM. High dose of spinal morphine produce a nonopiate receptor-mediated hyperesthesia: clinical and theoretic implications. Anesthesiology 1986; 64: 590–7PubMedCrossRef

10.

Shohami E, Evron S, Weinstock M, et al. A new animal model for action myoclonus. Adv Neurol 1986; 43: 545–52PubMed

11.

Christrup LL. Morphine metabolites. Acta Anaesthesiol Scand 1997; 41: 116–22PubMedCrossRef

12.

Dagan O, Klein J, Gruenwald C, et al. Preliminary studies of the effects of extracorporeal membrane oxygenator on the disposition of common pediatrie drugs. Ther Drug Monit 1993; 15: 263–6PubMedCrossRef

13.

Dagan O, Klein J, Bohn D, et al. Effects of extracorporeal membrane oxygenation on morphine pharmacokinetics in infants. Crit Care Med 1994; 22: 1099–101PubMedCrossRef

14.

Peters JWB, Anderson BJ, Simons SHP, et al. Morphine Pharmacokinetics during venoarterial extracorporeal membrane oxygenation in neonates. Intensive Care Med 2005; 31: 257–63PubMedCrossRef

15.

Bouwmeester J, Andersen B, Tibboel D, et al. Developmental pharmacokinetics of morphine and metabolites in neonates, infants, and children. Br J Anaesth 2004; 92: 208–17PubMedCrossRef

16.

Anderson B. Disentangling PK-PD in neonates. Arch Dis Child Fetal Neonatal Ed 2004; 89: F3–4PubMedCrossRef

17.

Penson RT, Joel SP, Clark S, et al. Limited phase I study of morphine-3-glucuronide. J Pharm Sci 2001; 90: 1810–6PubMedCrossRef

18.

Hanna MH, Peat SJ, Knibb AA, et al. Disposition of morphine-6-glucuronide and morphine in healthy volunteers. Br J Anaesth 1991; 66: 103–7PubMedCrossRef

19.

Holford NHG. A size standard for pharmacokinetics. Clin Pharmacokinet 1996; 30: 329–32PubMedCrossRef

20.

Verwey-van Wissen CP, Koopman-Kimenai PM, Vree TB. Direct determination of codeine, norcodeine, morphine and normorphine with their corresponding O-glucuronide conjugates by high-performance liquid chromatography with electrochemical detection. J Chromotogr 1991; 570: 309–20CrossRef

21.

West GB, Brown JH, Enquist BJ. A general model for the origin of allometric scaling laws in biology. Science 1997; 276: 122–6PubMedCrossRef

22.

Peters HP. Chpt 4. Physiological correlates of size. In: Beck E, Birks HJB, Conner EF, editors. The ecological implications of body size. Cambridge: Cambridge University Press, 1983: 48–53CrossRef

23.

Karalis V, Macheras P. Drug disposition viewed in terms of the fractal volume of distribution. Pharm Res 2002; 19: 696–703PubMed

24.

Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16: 31–41PubMedCrossRef

25.

Berkenstadt H, Segal E, Mayan H, et al. The pharmacokinetics of morphine and lidocaine in critically ill patients. Intensive Care Med 1999; 25: 110–2PubMedCrossRef

26.

Lynn A, Nespeca MK, Bratton SL, et al. Clearance of morphine in postoperative infants during intravenous infusion: the influence of age and surgery. Anesth Analg 1998; 86: 958–63PubMed

27.

Pokela ML, Olkkola KT, Seppala T, et al. Age-related morphine kinetics in infants. Dev Pharmacol Ther 1993; 20: 26–34PubMed

28.

Dagan O, Klein J, Bohn D, et al. Morphine pharmacokinetics in children following cardiac surgery: effects of disease and inotropic support. J Cardiothorac Vase Anesth 1993; 7: 396–8CrossRef

29.

Hasselstrom J, Sawe J. Morphine pharmacokinetics and metabolism in humans. Enterohepatic cycling and relative contribution of metabolites to active opioid concentrations. Clin Pharmacokinet 1993; 24: 344–54PubMedCrossRef

30.

Van Crugten JT, Sallustio BC, Nation RL, et al. Renal tubular transport of morphine, morphine-6-glucuronide, and morphine-3-glucuronide in the isolated perfused rat kidney. Drug Metab Dispos 1991; 19: 1087–92PubMed

31.

Bjornsson TD. Use of serum creatinine concentrations to determine renal function. Clin Pharmacokinet 1979; 4: 200–22PubMedCrossRef

32.

Lynn AM, Nespeca MK, Bratton SL, et al. Intravenous morphine in postoperative infants: intermittent bolus dosing versus targeted continuous infusions. Pain 2000; 88: 89–95PubMedCrossRef

33.

McRorie TI, Lynn AM, Nespeca M, et al. The maturation of morphine clearance and metabolism. Am J Dis Child 1992; 146: 972–6PubMed

34.

de Wildt SN, Kearns GL, Leeder JS, et al. Glucuronidation in humans: pharmacogenetic and developmental aspects. Clin Pharmacokinet 1999; 36: 439–52PubMedCrossRef

35.

Oda Y, Mizutani K, Hase I, et al. Fentanyl inhibits metabolism of midazolam: competitive inhibition of CYP3A4 in vitro. Br J Anaesth 1999; 82: 900–3PubMedCrossRef

36.

Geiduschek JM, Lynn AM, Bratton SL, et al. Morphine pharmacokinetics during continuous infusion of morphine sulfate for infants receiving extracorporeal membrane oxygenation. Crit Care Med 1997; 25: 360–4PubMedCrossRef

Title: Morphine Metabolite Pharmacokinetics during Venoarterial Extra Corporeal Membrane Oxygenation in Neonates
Authors: Dr Jemen W. B. Peters
Brian J. Anderson
Sinno H. P. Simons
Donald R. A. Uges
Dick Tibboel
Publication date: 01-07-2006
Publisher: Springer International Publishing
Published in: Clinical Pharmacokinetics / Issue 7/2006
Print ISSN: 0312-5963
Electronic ISSN: 1179-1926
DOI: https://doi.org/10.2165/00003088-200645070-00005

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Morphine Metabolite Pharmacokinetics during Venoarterial Extra Corporeal Membrane Oxygenation in Neonates

Abstract

Objective

Patients and methods

Results

Conclusion

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Objective

Patients and methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 7/2006

A Mechanistic Approach for the Scaling of Clearance in Children

Tipranavir

Modelling the Anti-Migraine Effects of BIBN 4096 BS

Cerebrospinal Fluid Distribution of Ketoprofen after Intravenous Administration in Young Children

Equivalent Pharmacokinetics of the Active Metabolite of Ciclesonide With and Without Use of the AeroChamber Plus™ Spacer for Inhalation

Pharmacokinetic/Pharmacodynamic Profile of Voriconazole